We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Biomarkers for Diabetic Kidney Disease to Improve Diagnosis and Monitoring

By LabMedica International staff writers
Posted on 08 Jan 2024

Diabetic kidney disease (DKD) is a major microvascular complication arising from type 2 diabetes mellitus (T2DM), leading to end-stage renal disease (ESRD). More...

Despite advancements in treatment options such as hyperglycemic and blood pressure control and renin-angiotensin system blockades, DKD continues to prevail at alarming rates. Clinically, DKD often progresses from microalbuminuria to macroalbuminuria, marked by increased levels of albumin in the urine and an initial hyperfiltration phase followed by a gradual decline in renal function. However, variations in clinical presentations and progression rates to ESRD have been noted in recent studies. As scientific understanding evolves, the need for specific biomarkers for DKD has become increasingly vital. Now, an analysis of urinary and exosome proteome profiling by a team of scientists has led to the discovery of biomarkers for DKD, offering the potential for early diagnosis and treatment.

The research carried out by scientists at the Chinese Academy of Sciences (Beijing, China) involved extensive urinary proteomics analysis of 144 patients and urinary exosome proteomics of 44 patients with varying degrees of albuminuria related to T2DM. Utilizing exosomes for biomarker discovery offers several benefits, including minimizing the presence of abundant proteins in urine and enriching a subproteome comprising membrane and cytosolic proteins. Urinary exosomes also provide crucial information from a wide range of epithelial origins, reflecting physiological or pathological processes in virtually all epithelial cells exposed to the urinary space. Additionally, proteomic analysis of urinary exosomes can identify proteins specifically linked to certain kidney diseases, as was the case in this study.

The study analyzed urine samples from 144 clinical patients, including 19 healthy controls and 125 DM patients. The diabetic group was further categorized into three stages based on albumin-to-creatinine ratio (ACR) values. The research highlighted the dynamic nature of urinary and exosome proteomes in T2DM patients at different albuminuria stages. Proteins were grouped into six clusters based on their expression patterns throughout DKD progression. The study observed a significant decrease in proteins associated with glycolytic and ubiquitination processes from healthy controls to early DM stages, with a gradual decrease continuing to the late DM stages. Conversely, proteins involved in lipid transport and cholesterol esterification progressively increased, peaking at the most advanced stage. Proteins involved in carbohydrate metabolic processes showed high expression in early DM patients, decreasing as DKD progressed. Additionally, the study identified and validated potential biomarkers for DKD diagnosis or disease monitoring, such as SERPINA1 and TF, in another cohort of diabetic urine samples with varying DKD degrees. Thus, this research has provided a deeper understanding of the biomarkers associated with renal disease, fueling hopes for improved early-stage treatments and management strategies for DKD.

Related Links:
Chinese Academy of Sciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.